Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Short Interest Update

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 13,100 shares, a decline of 42.5% from the August 15th total of 22,800 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Laboratorios Farmaceuticos Rovi Stock Performance

Laboratorios Farmaceuticos Rovi stock opened at C$54.13 on Friday. The company’s 50-day moving average price is C$51.14 and its 200-day moving average price is C$51.11. Laboratorios Farmaceuticos Rovi has a twelve month low of C$50.10 and a twelve month high of C$51.10.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmaceuticos Rovi, SA engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa.